Skip to main content

AbbVie Inc.

corporate_fare Company Profile

AbbVie Inc.

ABBV·NYSE·Life Sciences·CIK 0001551152

AbbVie is a global, diversified research-based biopharmaceutical company that develops and markets advanced therapies. The company was incorporated in Delaware on April 10, 2012, and became an independent, publicly-traded company on January 1, 2013, following a distribution from Abbott Laboratories. AbbVie operates as a single global business segment, focusing on the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies. This structure allows the Chief Executive Officer to allocate resources and assess performance globally. A global research and development and supply chain organization handles product discovery, development, manufacturing, and supply, while commercial efforts for marketing, sales, and distribution are organized by geographic region or therapeutic area. These activities are supported by a global corporate administrative staff. AbbVie's product portfolio holds leadership positions across immunology, neuroscience, oncology, and aesthetics. Its products include a broad line of therapies for complex and serious diseases, with an extensive immunology portfolio covering rheumatology, dermatology, and gastroenterology.

AbbVie Inc. (NYSE:ABBV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 53 items for ABBV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 12 rated 8 or above. Recent SEC coverage for ABBV spans 8-K, FWP, 424B5, 10-Q.

Recent high-impact activity:

  • AbbVie's Atogepant Hits Primary Endpoint in Phase 3 Menstrual Migraine Trial
  • AbbVie's Atogepant Hits Phase 3 Goals in Menstrual Migraine, Plans Global Filings
  • AbbVie's Etentamig Hits Primary Endpoints in Phase 3 Myeloma Trial
  • AbbVie's Etentamig Hits Dual Primary Endpoints in Phase 3 Multiple Myeloma Trial
  • AbbVie Closes $10.9B Apogee Deal, Reaffirms 2026 EPS Outlook

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$61.16B
Net Income
$4.23B
Diluted EPS
$2.36
Op. Cash Flow
$19.03B
Free Cash Flow
$17.82B
Gross Profit
$42.96B
Operating Income
$15.07B
Cash & Equivalents
$5.23B
Total Debt
$2.5B
Debt / Equity
-0.76×
Net Margin
6.9%
Shares Outstanding
1.77B sh
Source: 10-K · filed 2026-02-20 · accession 0001551152-26-000008

Dilution Risk

Low risk

Filing-implied dilution signals for ABBV, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

1 recent capital raise

Bond Offering Finalized · Proceeds to Fund Apogee Acquisition

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$257.6 +0.48% today
52-week range · as of 2026-09-03 $190.75 – $267.47
Market cap
$454.36B
Volume
4.3M (0.9× avg)
3-mo avg 4.7M
Live data · 2026-09-13 00:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABBV - Latest Insights

ABBV
Sep 10, 2026, 12:41 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $252.45
Real-time Price: $257.60 info
Change: +$5.16 (+2%) info
Market Cap: $454.361B info
ABBV
Sep 10, 2026, 9:38 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $252.41
Real-time Price: $257.60 info
Change: +$5.19 (+2%) info
Market Cap: $454.361B info
ABBV
Sep 03, 2026, 2:10 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $260.74
Real-time Price: $257.60 info
Change: -$3.14 (-1%) info
Market Cap: $454.361B info
ABBV
Sep 03, 2026, 9:42 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $260.55
Real-time Price: $257.60 info
Change: -$2.94 (-1%) info
Market Cap: $454.361B info
ABBV
Sep 03, 2026, 8:47 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $262.44
Real-time Price: $257.60 info
Change: -$4.84 (-2%) info
Market Cap: $454.361B info
ABBV
Aug 26, 2026, 1:00 AM EDT
Source: MFN by Modular Finance
Importance Score:
7
Price at Filing: $265.32
Real-time Price: $257.60 info
Change: -$7.72 (-3%) info
Market Cap: $454.361B info
ABBV
Aug 04, 2026, 9:22 PM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $244.55
Real-time Price: $257.60 info
Change: +$13.05 (+5%) info
Market Cap: $454.361B info
ABBV
Aug 04, 2026, 8:18 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $247.50
Real-time Price: $257.60 info
Change: +$10.10 (+4%) info
Market Cap: $454.361B info
ABBV
Aug 03, 2026, 2:14 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $246.39
Real-time Price: $257.60 info
Change: +$11.21 (+5%) info
Market Cap: $454.361B info
ABBV
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $252.93
Real-time Price: $257.60 info
Change: +$4.67 (+2%) info
Market Cap: $454.361B info
ABBV
Jul 31, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $250.00
Real-time Price: $257.60 info
Change: +$7.60 (+3%) info
Market Cap: $454.361B info
ABBV
Jul 31, 2026, 7:47 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $256.01
Real-time Price: $257.60 info
Change: +$1.59 (+0.62%) info
Market Cap: $454.361B info
ABBV
Jul 30, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $263.50
Real-time Price: $257.60 info
Change: -$5.90 (-2%) info
Market Cap: $454.361B info
ABBV
Jul 29, 2026, 5:55 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $265.50
Real-time Price: $257.60 info
Change: -$7.90 (-3%) info
Market Cap: $454.361B info
ABBV
Jul 23, 2026, 4:59 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $255.46
Real-time Price: $257.60 info
Change: +$2.14 (+0.84%) info
Market Cap: $454.361B info
ABBV
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $256.94
Real-time Price: $257.60 info
Change: +$0.6645 (+0.26%) info
Market Cap: $454.361B info
ABBV
Jul 17, 2026, 8:37 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $256.86
Real-time Price: $257.60 info
Change: +$0.740 (+0.29%) info
Market Cap: $454.361B info
ABBV
Jul 06, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $255.50
Real-time Price: $257.60 info
Change: +$2.10 (+0.82%) info
Market Cap: $454.361B info
ABBV
Jul 06, 2026, 1:45 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $256.48
Real-time Price: $257.60 info
Change: +$1.12 (+0.44%) info
Market Cap: $454.361B info
ABBV
Jul 06, 2026, 7:19 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $261.00
Real-time Price: $257.60 info
Change: -$3.40 (-1%) info
Market Cap: $454.361B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets